Merck Frosst Canada, Inc.

Merck + Co., Inc.

Merck Frosst Canada & Co.

Merck Sharp + Dohme Corp.

Yves Girard

Pierre A Hamel

Daniel Dube

John W Gillard

Rejean Fortin

Yvan Guindon

Yves Ducharme

Christiane Yoakim

Daniel Delorme

John Howard Hutchinson

Richard W Friesen

Michel Gallant

Patrick Lacombe

John Scheigetz

Clarence S Rooney

Joshua Rokach

Daniel Guay

Howard E Morton

Joseph G Atkinson

Richard Frenette

Edward L Engelhardt

Marc Blouin

Mario Girard

Denis Deschenes

Dwight Macdonald

Robert N Young

Michel Therien

Laurence Dube

Dwight MacDonald

Laird A Trimble

Chun Li

Cheuk K Lau

Erich L Grimm

Renee Aspiotis

Helene Perrier

Deborah A Nicoll-Griffith

James A Yergey

Cedrickx Godbout

Anthony Mastracchio

Mark T Goulet

Feroze Ujjainwalla

Lin Chu

Linda L Chang

John Y Chung

Robert A Reamer

Sebastien Laliberte

Bernard Cote

Sylvie Prescott

Nathalie Chauret

Rick Friesen

Annette Robichoud

Yvbes Ducharme

Daaniel Guay

Carol Lepine

The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents. 

Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use

This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or condition 

Quinolinones as prostaglandin receptor ligands

Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition 

4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.

4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors

8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression, memory impairment, tumour growth, or cancerous invasion of normal tissues. In another aspect, the present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and cognition enhancing amount of a phosphodiesterase-4 inhibitor.

8-(biaryl)quinoline PDE4 inhibitors

8-arylquinolines of formula (I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, and other diseases. R-Rand Ar are as in claim

Substituted 8-arylquinolune PDE4 inhibitors

1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors

A PDE4 inhibiting compound is represented by

Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor

Novel substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.

Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

The invention encompasses compounds of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3&prime;,5&prime;-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).

PDE IV inhibiting compounds, compositions and methods of treatment

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3&prime;,5&prime;-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4).

Heterosubstituted pyridine derivatives as PDE4 inhibitors

Heterosubstituted pyridine derivatives as PDE 4 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.

Diphenyl pyridyl ethane derivatives as PDE IV inhibitors

Tri-aryl ethane derivatives as PDE IV inhibitors

Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

Arylbicyclooctanes as inhibitors of leukotriene biosynthesis

Growing community of inventors

Ile-Bizard, Canada

Yves Girard